Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 11.4% | 22.2% | 67.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.8% | 57.5% | 45.2% | 54.4% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 54.1% | 54.4% | 37.4% | 31.3% |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 11% | 8.5% | -5.4% | 25.8% |
| EPS Diluted | 1.86 | 1.29 | -0.74 | 1.86 |
| % Growth | 44.2% | 274.3% | -139.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |